Chemokines and inflammation in heart disease: Adaptive or maladaptive?

International Journal of Clinical and Experimental Medicine

Volumn 4, Issue 1, 2011, Pages 74-80

  Tarzami, Sima T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Chemokines; Congestive heart failure; Inflammation; Myocardial infarction; Stem cell therapy

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR4; G PROTEIN COUPLED RECEPTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 2 RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

AUTOCRINE EFFECT; CYTOKINE RELEASE; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HEART STRESS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFLAMMATION; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PARACRINE SIGNALING; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; STEM CELL MOBILIZATION;

ANIMALIA;

EID: 79951689557     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Manuel DG, Wilson S, Maaten S: The 2006 canadian dyslipidemia guidelines will prevent more deaths while treating fewer people--but should they be further modified? The Canadian journal of cardiology 2008;24:617-620.
2. Spertus JA, Radford MJ, Every NR, Ellerbeck EF,Peterson ED, Krumholz HM: Challenges and opportunities in quantifying the quality of care for acute myocardial infarction: Summary from the acute myocardial infarction working group of the american heart association/American college of cardiology first scientific forum on quality of care and outcomes research in cardiovascular disease and stroke. Circulation 2003;107:1681-1691.
3. Ryan TJ, Anderson JL, Antman EM, Braniff BA,Brooks NH, Califf RM, Hillis LD, Hiratzka LF,Rapaport E, Riegel BJ, Russell RO, Smith EE, Jr.,Weaver WD: Acc/aha guidelines for the management of patients with acute myocardial infarction. A report of the american college of cardiology/american heart association task force on practice guidelines (committee on management of acute myocardial infarction). J Am Coll Cardiol 1996;28:1328-1428.
4. De Luca G, Suryapranata H, Marino P: Reperfusion strategies in acute st-elevation myocardial infarction: An overview of current status. Progress in cardiovascular diseases 2008;50:352-382.
5. Chen J, Chemaly E, Liang L, Kho C, Lee A, Park J, Altman P, Schecter AD, Hajjar RJ, Tarzami ST: Effects of cxcr4 gene transfer on cardiac function after ischemia-reperfusion injury. Am J Pathol;176:1705-1715.
6. Pyo RT, Sui J, Dhume A, Palomeque J, Blaxall BC, Diaz G, Tunstead J, Logothetis DE, Hajjar RJ, Schecter AD: Cxcr4 modulates contractility in adult cardiac myocytes. J Mol Cell Cardiol 2006;41:834-844.
7. Entman ML, Smith CW: Postreperfusion inflammation: A model for reaction to injury in cardiovascular disease. Cardiovasc Res 1994;28:1301-1311.
8. Frangogiannis NG, Entman ML: Targeting the chemokines in myocardial inflammation. Circulation 2004;110:1341-1342.
9. Balabanian K, Harriague J, Decrion C, Lagane B, Shorte S, Baleux F, Virelizier JL, Arenzana- Seisdedos F, Chakrabarti LA: Cxcr4-tropic hiv-1 envelope glycoprotein functions as a viral chemokine in unstimulated primary cd4+ t lymphocytes. J Immunol 2004;173:7150-7160.
10. Roberts R, DeMello V, Sobel BE: Deleterious effects of methylprednisolone in patients with myocardial infarction. Circulation 1976;53:I204-1206.
11. Jolly SR, Kane WJ, Hook BG, Abrams GD,Kunkel SL, Lucchesi BR: Reduction of myocardial infarct size by neutrophil depletion: Effect of duration of occlusion. American heart journal 1986;112:682-690.
12. Litt MR, Jeremy RW, Weisman HF, Winkelstein JA, Becker LC: Neutrophil depletion limited to reperfusion reduces myocardial infarct size after 90 minutes of ischemia. Evidence for neutrophil-mediated reperfusion injury. Circulation 1989;80:1816-1827.
13. Frangogiannis NG, Smith CW, Entman ML: The inflammatory response in myocardial infarction. Cardiovasc Res 2002;53:31-47.
14. Gordon JR, Galli SJ: Mast cells as a source of both preformed and immunologically inducible tnf-alpha/cachectin. Nature 1990;346:274-276.
15. Maury CP, Teppo AM: Circulating tumour necrosis factor-alpha (cachectin) in myocardial infarction. Journal of internal medicine 1989;225:333-336.
16. Ikeda U, Ohkawa F, Seino Y, Yamamoto K, Hidaka Y, Kasahara T, Kawai T, Shimada K: Serum interleukin 6 levels become elevated in acute myocardial infarction. J Mol Cell Cardiol 1992;24:579-584.
17. Cruickshank AM, Oldroyd KG, Cobbe SM: Serum interleukin-6 in suspected myocardial infarction. Lancet 1994;343:974.
18. Miyao Y, Yasue H, Ogawa H, Misumi I, Masuda T, Sakamoto T, Morita E: Elevated plasma interleukin- 6 levels in patients with acute myocardial infarction. American heart journal 1993;126:1299-1304.
19. Basaran Y, Basaran MM, Babacan KF, Ener B, Okay T, Gok H, Ozdemir M: Serum tumor necrosisfactor levels in acute myocardial infarction and unstable angina pectoris. Angiology 1993;44:332-337.
20. Deten A, Volz HC, Briest W, Zimmer HG: Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats. Cardiovasc Res 2002;55:329-340.
21. Dove A: Cd18 trials disappoint again. Nature biotechnology 2000;18:817-818.
22. Anker SD, Coats AJ: How to recover from renaissance? The significance of the results of recover, renaissance, renewal and attach. International journal of cardiology 2002;86:123-130.
23. Anker SD, von Haehling S: Inflammatory mediators in chronic heart failure: An overview. Heart 2004;90:464-470.
24. Mann DL: Inflammatory mediators and the failing heart: Past, present, and the foreseeable future. Circ Res 2002;91:988-998.
25. Rollins BJ: Chemokines. Blood 1997;90:909-928.
26. Stroud RM, Wells JA: Mechanistic diversity of cytokine receptor signaling across cell membranes. Sci STKE 2004;2004:re7.
27. Horuk R: The interleukin-8-receptor family: From chemokines to malaria. Immunol Today 1994;15:169-174.
28. Seino Y, Ikeda U, Sekiguchi H, Morita M, Konishi K, Kasahara T, Shimada K: Expression of leukocyte chemotactic cytokines in myocardial tissue. Cytokine 1995;7:301-304.
29. Shioi T, Matsumori A, Kihara Y, Inoko M, Ono K,Iwanaga Y, Yamada T, Iwasaki A, Matsushima K, Sasayama S: Increased expression of interleukin- 1 beta and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the hypertrophied and failing heart with pressure overload. Circ Res 1997;81:664-671.
30. Behr TM, Wang X, Aiyar N, Coatney RW, Li X,Koster P, Angermann CE, Ohlstein E, Feuerstein GZ, Winaver J: Monocyte chemoattractant protein- 1 is upregulated in rats with volumeoverload congestive heart failure. Circulation 2000;102:1315-1322.
31. Kukielka GL, Youker KA, Michael LH, Kumar AG, Ballantyne CM, Smith CW, Entman ML: Role of early reperfusion in the induction of adhesion molecules and cytokines in previously ischemic myocardium. Mol Cell Biochem 1995;147:5-12.
32. Frangogiannis NG, Mendoza LH, Lewallen M,Michael LH, Smith CW, Entman ML: Induction and suppression of interferon-inducible protein 10 in reperfused myocardial infarcts may regulate angiogenesis. Faseb J 2001;15:1428-1430.
33. Tarzami ST, Cheng R, Miao W, Kitsis RN, Berman JW: Chemokine expression in myocardial ischemia: Mip-2 dependent mcp-1 expression protects cardiomyocytes from cell death. J Mol Cell Cardiol 2002;34:209-221.
34. Tarzami ST, Miao W, Mani K, Lopez L, Factor SM, Berman JW, Kitsis RN: Opposing effects mediated by the chemokine receptor cxcr2 on myocardial ischemia-reperfusion injury: Recruitment of potentially damaging neutrophils and direct myocardial protection. Circulation 2003;108:2387-2392.
35. Tarzami ST, Calderon TM, Deguzman A, Lopez L, Kitsis RN, Berman JW: Mcp-1/ccl2 protects cardiac myocytes from hypoxia-induced apoptosis by a g(alphai)-independent pathway. Biochem Biophys Res Commun 2005;335:1008-1016.
36. Khan MZ, Brandimarti R, Patel JP, Huynh N,Wang J, Huang Z, Fatatis A, Meucci O: Apoptotic and antiapoptotic effects of cxcr4: Is it a matter of intrinsic efficacy? Implications for hiv neuropathogenesis. AIDS research and human retroviruses 2004;20:1063-1071.
37. Hu X, Dai S, Wu WJ, Tan W, Zhu X, Mu J, Guo Y,Bolli R, Rokosh G: Stromal cell derived factor-1 alpha confers protection against myocardial ischemia/reperfusion injury: Role of the cardiac stromal cell derived factor-1 alpha cxcr4 axis. Circulation 2007;116:654-663.
38. Penn MS, Zhang M, Deglurkar I, Topol EJ: Role of stem cell homing in myocardial regeneration. International journal of cardiology 2004;95 Suppl 1:S23-25.
39. Colamussi ML, Secchiero P, Zella D, Curreli S,Mirandola P, Capitani S, Zauli G: Stromal derived factor-1alpha induces apoptosis in activated primary cd4+ t cells. AIDS (London, England) 2000;14:748-750.
40. Ilhan A, Nabokikh A, Maj M, Vidakovic M, Nielsen JH, Prikoszovich T, Niederle B, Base W,Luger A, Wagner L: Cxcl12/sdf-1 overexpression in human insulinomas and its biological relevance. Molecular and cellular endocrinology 2009;298:1-10.
41. LaRocca TJ, Schwarzkopf M, Altman P, Zhang S,Gupta A, Gomes I, Alvin Z, Champion HC,Haddad G, Hajjar RJ, Devi LA, Schecter AD,Tarzami ST: Beta2-adrenergic receptor signaling in the cardiac myocyte is modulated by interactions with cxcr4. J Cardiovasc Pharmacol
42. Limbourg FP, Ringes-Lichtenberg S, Schaefer A,Jacoby C, Mehraein Y, Jager MD, Limbourg A,Fuchs M, Klein G, Ballmaier M, Schlitt HJ,Schrader J, Hilfiker-Kleiner D, Drexler H: Haematopoietic stem cells improve cardiac function after infarction without permanent cardiac engraftment. Eur J Heart Fail 2005;7:722-729.
43. Beltrami AP, Barlucchi L, Torella D, Baker M,Limana F, Chimenti S, Kasahara H, Rota M,Musso E, Urbanek K, Leri A, Kajstura J, Nadal- Ginard B, Anversa P: Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003;114:763-776.
44. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, Homma S, Edwards NM,Itescu S: Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001;7:430-436.
45. Hughes S: Cardiac stem cells. The Journal of pathology 2002;197:468-478.
46. Britten MB, Abolmaali ND, Assmus B, Lehmann R, Honold J, Schmitt J, Vogl TJ, Martin H,Schachinger V, Dimmeler S, Zeiher AM: Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (topcare-ami): Mechanistic insights from serial contrast-enhanced magnetic resonance imaging. Circulation 2003;108:2212-2218.
47. Laflamme MA, Zbinden S, Epstein SE, Murry CE: Cell-based therapy for myocardial ischemia and infarction: Pathophysiological mechanisms. Annu Rev Pathol 2007;2:307-339.
48. Jain M, DerSimonian H, Brenner DA, Ngoy S,Teller P, Edge AS, Zawadzka A, Wetzel K, Sawyer DB, Colucci WS, Apstein CS, Liao R: Cell therapy attenuates deleterious ventricular remodeling and improves cardiac performance after myocardial infarction. Circulation 2001;103:1920-1927.
49. Orlic D, Kajstura J, Chimenti S, Jakoniuk I,Anderson SM, Li B, Pickel J, McKay R, Nadal- Ginard B, Bodine DM, Leri A, Anversa P: Bone marrow cells regenerate infarcted myocardium. Nature 2001;410:701-705.
50. Murry CE, Soonpaa MH, Reinecke H, Nakajima H, Nakajima HO, Rubart M, Pasumarthi KB,Virag JI, Bartelmez SH, Poppa V, Bradford G,Dowell JD, Williams DA, Field LJ: Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004;428:664-668.
51. Toma C, Pittenger MF, Cahill KS, Byrne BJ,Kessler PD: Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002;105:93-98.
52. Oh H, Bradfute SB, Gallardo TD, Nakamura T,Gaussin V, Mishina Y, Pocius J, Michael LH,Behringer RR, Garry DJ, Entman ML, Schneider MD: Cardiac progenitor cells from adult myocardium: Homing, differentiation, and fusion after infarction. Proc Natl Acad Sci U S A 2003;100:12313-12318.
53. Mummery C, Ward-van Oostwaard D, Doevendans P, Spijker R, van den Brink S, Hassink R,van der Heyden M, Opthof T, Pera M, de la Riviere AB, Passier R, Tertoolen L: Differentiation of human embryonic stem cells to cardiomyocytes: Role of coculture with visceral endoderm- like cells. Circulation 2003;107:2733-2740.
54. Kang HJ, Kim HS, Zhang SY, Park KW, Cho HJ,Koo BK, Kim YJ, Soo Lee D, Sohn DW, Han KS,Oh BH, Lee MM, Park YB: Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: The magic cell randomised clinical trial. Lancet 2004;363:751-756.
55. Dimmeler S: Regulation of bone marrowderived vascular progenitor cell mobilization and maintenance. Arteriosclerosis, thrombosis, and vascular biology;30:1088-1093.
56. Jo DY, Rafii S, Hamada T, Moore MA: Chemotaxis of primitive hematopoietic cells in response to stromal cell-derived factor-1. J Clin Invest 2000;105:101-111.
57. Moore MA, Hattori K, Heissig B, Shieh JH, Dias S, Crystal RG, Rafii S: Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of sdf-1, vegf, and angiopoietin-1. Annals of the New York Academy of Sciences 2001;938:36-45; discussion 45-37.
58. Hiasa K, Ishibashi M, Ohtani K, Inoue S, Zhao Q, Kitamoto S, Sata M, Ichiki T, Takeshita A,Egashira K: Gene transfer of stromal cellderived factor-1alpha enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: Nextgeneration chemokine therapy for therapeutic neovascularization. Circulation 2004;109:2454-2461.
59. Abbott JD, Huang Y, Liu D, Hickey R, Krause DS,Giordano FJ: Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation 2004;110:3300-3305.
60. Tendera M, Wojakowski W, Ruzyllo W, Chojnowska L, Kepka C, Tracz W, Musialek P, Piwowarska W, Nessler J, Buszman P, Grajek S,Breborowicz P, Majka M, Ratajczak MZ: Intracoronary infusion of bone marrow-derived selected cd34+cxcr4+ cells and non-selected mononuclear cells in patients with acute stemi and reduced left ventricular ejection fraction: Results of randomized, multicentre myocardial regeneration by intracoronary infusion of selected population of stem cells in acute myocardial infarction (regent) trial. Eur Heart J 2009;30:1313-1321.
61. Onuffer JJ, Horuk R: Chemokines, chemokine receptors and small-molecule antagonists: Recent developments. Trends in pharmacological sciences 2002;23:459-467.
62. Chen C, Li J, Bot G, Szabo I, Rogers TJ, Liu-Chen LY: Heterodimerization and crossdesensitization between the mu-opioid receptor and the chemokine ccr5 receptor. European journal of pharmacology 2004;483:175-186.
63. Insel PA, Tang CM, Hahntow I, Michel MC: Impact of gpcrs in clinical medicine: Monogenic diseases, genetic variants and drug targets. Biochimica et biophysica acta 2007;1768:994-1005.